Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance.

ABSTRACT:

Aim

Invasive lobular carcinoma (ILC) is the second most common breast cancer type after invasive ductal carcinoma (IDC). Eribulin mesylate (eribulin) is a non-taxane microtubule dynamics inhibitor approved for advanced or metastatic breast cancer, including ILC and IDC. However, real-world data from eribulin-treated patients with advanced or metastatic ILC are scarce.

Methods

This post hoc analysis of a Japanese multicenter, prospective, observational post-marketing surveillance (ClinicalTrials.gov: NCT02371174) evaluated data from eribulin-treated patients with ILC or IDC. Overall survival (OS) from the initiation of first-line chemotherapy, OS from the first date of eribulin administration, and time-to-treatment failure (TTF) were evaluated. OS from eribulin initiation was

SUBMITTER: Tanabe Y 

PROVIDER: S-EPMC12582348 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature